141 related articles for article (PubMed ID: 9762542)
1. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression.
Bànkfalvi A; Terpe HJ; Breukelmann D; Bier B; Rempe D; Pschadka G; Krech R; Böcker W
Histopathology; 1998 Aug; 33(2):107-16. PubMed ID: 9762542
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44.
Bànkfalvi A; Terpe HJ; Breukelmann D; Bier B; Rempe D; Pschadka G; Krech R; Lellè RJ; Boecker W
Histopathology; 1999 Jan; 34(1):25-34. PubMed ID: 9934581
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
[TBL] [Abstract][Full Text] [Related]
4. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression.
Bánkfalvi A; Krassort M; Buchwalow IB; Végh A; Felszeghy E; Piffkó J
J Pathol; 2002 Nov; 198(3):343-51. PubMed ID: 12375267
[TBL] [Abstract][Full Text] [Related]
5. CD44 loss in gastric stromal tumors as a prognostic marker.
Montgomery E; Abraham SC; Fisher C; Deasel MR; Amr SS; Sheikh SS; House M; Lilliemoe K; Choti M; Brock M; Ephron DT; Zahuruk M; Chadburn A
Am J Surg Pathol; 2004 Feb; 28(2):168-77. PubMed ID: 15043305
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of CD44 isoform expression in endometrial cancer.
Tempfer C; Haeusler G; Kaider A; Hefler L; Hanzal E; Reinthaller A; Breitenecker G; Kainz C
Br J Cancer; 1998 Apr; 77(7):1137-9. PubMed ID: 9569051
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.
Tran TA; Kallakury BV; Sheehan CE; Ross JS
Hum Pathol; 1997 Jul; 28(7):809-14. PubMed ID: 9224749
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours.
Imam H; Eriksson B; Oberg K
Ann Oncol; 2000 Mar; 11(3):295-300. PubMed ID: 10811495
[TBL] [Abstract][Full Text] [Related]
10. CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer.
Tempfer C; Sliutz G; Haeusler G; Speiser P; Reinthaller A; Breitenecker G; Vavra N; Kainz C
Br J Cancer; 1998 Oct; 78(8):1091-4. PubMed ID: 9792156
[TBL] [Abstract][Full Text] [Related]
11. [Expression of CD44 isoforms in normal human liver and also in regenerative and neoplastic liver changes].
Seelentag WK; Flury R; Schmid M; Komminoth P; Saremaslani P; Günthert U; Heitz PU; Roth J
Verh Dtsch Ges Pathol; 1995; 79():144-7. PubMed ID: 8600679
[TBL] [Abstract][Full Text] [Related]
12. CD44 and variants in melanocytic skin neoplasms.
Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
Fichtner I; Dehmel A; Naundorf H; Finke LH
Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast.
Berner HS; Nesland JM
Breast Cancer Res Treat; 2001 Jan; 65(1):23-9. PubMed ID: 11245336
[TBL] [Abstract][Full Text] [Related]
15. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer.
Tempfer C; Lösch A; Heinzl H; Häusler G; Hanzal E; Kölbl H; Breitenecker G; Kainz C
Eur J Cancer; 1996 Oct; 32A(11):2023-5. PubMed ID: 8943691
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression.
Lu D; Tawfik O; Pantazis C; Hobart W; Chapman J; Iczkowski K
Gynecol Oncol; 1999 Oct; 75(1):84-90. PubMed ID: 10502431
[TBL] [Abstract][Full Text] [Related]
18. CD44 variant exon epitopes in primary breast cancer and length of survival.
Kaufmann M; Heider KH; Sinn HP; von Minckwitz G; Ponta H; Herrlich P
Lancet; 1995 Mar; 345(8950):615-9. PubMed ID: 7534855
[TBL] [Abstract][Full Text] [Related]
19. CD44 expression in soft tissue sarcomas.
Kahara N; Ozaki T; Doi T; Nishida K; Kawai A; Shibahara M; Inoue H
Virchows Arch; 2000 Jun; 436(6):574-8. PubMed ID: 10917171
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma.
Poncelet C; Walker F; Madelenat P; Bringuier AF; Scoazec JY; Feldmann G; Darai E
Hum Pathol; 2001 Nov; 32(11):1190-6. PubMed ID: 11727257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
